Pharmacogenomics is the first module of SeqOne Preventive Genomics. It turns your panels, exomes and genomes into star-allele diplotypes, phenotypes and guideline-backed drug recommendations, inside GermVar.




Call star alleles, including CYP2D6 copy number and hybrid alleles
Score every call from coverage, fit and separation before you sign
Compare CPIC, DPWG, FDA and RNPGx guidance side by side, drug by drug
Generate a PGx passport with key findings on page one, in your lab's colors
Pharmacogenomics is easy to order and hard to get right. CYP2D6 hides deletions, duplications and hybrids. CPIC and DPWG do not always agree. And PGx is often a second test on a sample you have already sequenced. SeqOne brings genotyping, evidence and reporting into the germline workflow your lab already runs.
Book a demo1. McInnes et al., Pharmacogenetics at scale: an analysis of the UK Biobank, 2021. 2. Swen et al., PREPARE trial, The Lancet, 2023. 3. European Commission estimate, 2008.
The PGx module runs inside GermVar, on the same FASTQ files as your germline analysis. No new sample, no second assay, no extra pipeline to validate.




DPYD · UGT1A1 · TPMT · NUDT15
Fluoropyrimidines, irinotecan and thiopurines, where a missed variant can cause severe toxicity.
CYP2C19 · SLCO1B1 · CYP2C9 · VKORC1
Clopidogrel, statins and vitamin K antagonists such as warfarin, acenocoumarol and fluindione.
CYP2D6 · CYP2C19 · CYP2B6
Antidepressants, codeine and tramadol, where metabolizer status changes efficacy and safety.
RYR1 · CACNA1S
Volatile anesthetics and succinylcholine in patients at risk of malignant hyperthermia.
HLA-B*57:01 · HLA-B*15:02 · HLA-A*31:01 · HLA-B*58:01
Abacavir, carbamazepine and allopurinol, where one HLA allele can predict a severe reaction.
MT-RNR1 · G6PD · NAT2
Aminoglycoside-induced hearing loss, primaquine and isoniazid.
The same analysis, QC and team review rare-disease variants and drug response.
Copy number, hybrids and phasing are part of the call, and every call carries its confidence.
CPIC and FDA sit next to DPWG, RNPGx, CPNDS, AusNZ and other national guidelines, so your lab follows the sources that apply where you practice.
Every recommendation shows where it comes from. No black box.
Add lab knowledge, set the source order and brand the report with your colors.
Each release is dated, so every report records the knowledge it used.

Validate the PGx module on your own samples, with expert support and zero commitment.
Pay per analysis, with no hidden fees or volume constraints.

Field specialists and multilingual help, from validation to your first signed report.
For now, SeqOne PGx supports short-read sequencing only: data from targeted gene panels, whole exomes and whole genomes, aligned to GRCh38. Long-read data is not supported yet. The module starts from the FASTQ files of your GermVar analysis, so there is no separate assay or pipeline to run. For a panel, the pharmacogenes you want to report must be in the capture design; we check this with you during setup.
PGx is included at no additional cost with WES and WGS analyses launched in GermVar. You get the drug-response profile from the same sequencing and analysis you already run for the diagnosis, with no new sample or assay. For targeted panels and other setups, your SeqOne contact will find the right option for your lab.
56 pharmacogenes plus HLA-A, -B and -C typing, more than 1,400 alleles with curated function and more than 160 drugs with recommendations from 11 sources: CPIC, DPWG, FDA, RNPGx, CPNDS, SEFF/SEOM, AIOM, AHA, ACR, CFF and AusNZ.
We validated the module on 56 samples against 4 reference truth sets: 98.9% genotype concordance, 99.2% phenotype concordance and 100% recall of the expected drug recommendations, above our 95% acceptance criterion. The validation summary is available on request.
Copy number is estimated from sequencing depth first and used to constrain the allele search, so deletions, duplications and CYP2D6/CYP2D7 hybrid alleles are part of the call. Every diplotype comes with quality scores, and warnings are raised in plain view, for example when a novel major allele is detected.
Yes. Click a gene in the PGx tab to see its quality scores, each variant phased on its allele, and the underlying calls with genotype, depth and VAF, with a link into the variant viewer. Nothing is hidden: you review the call before it reaches the report.
Yes. Before issuing, you choose the report type (a clinical report or a pre-emptive PGx passport), the genes and drugs reported, the guideline sources and their order, and the impact levels shown. The report carries your logo and colors, is signed in the platform and records the knowledge-base version used.
Yes. Add lab knowledge and choose whether it comes before public guidance or replaces it.
No. PGx is an option you pick when launching an analysis. You keep QC, gene coverage and the variant viewers, and get a PGx tab on top, so one run can give both the genetic report and the PGx report. Analyses launched without the option run exactly as before.
No. The PGx knowledge base runs inside the platform, and no third-party service is called during the analysis. The knowledge base is versioned and its version is stamped on every result.
This is on our roadmap: results from Thermo Fisher OpenArray, Agena MassARRAY, Pleno and DRAGEN will feed the same PGx tables and reports.